The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia fluctuate in the range of ±30%. Considering the current vol-ume of
antipsychotic drug supply, replacing 100
Clinical and economic efficiency of treatment with cariprazine in schizophrenia, the costs related to treatment of patients with a
second generation antipsychotics funded by the state
Опыт применения карипразина при лечении шизофрении и биполярного аффективного расстройства. The drug shows high efficacy against negative symptoms. The side effects most characteristic of
second-generation Association of a Single-Nucleotide Variant rs11100494 of the NPY5R Gene with Antipsychotic-Induced Metabolic DisordersDobrodeeva, V.S.,
Shnayder, N.A.,
Novitsky, M.A.,
Asadullin, A.R.,
Vaiman, E.E.,
Petrova, M.M.,
Limankin, O.V.,
Neznanov, N.G.,
Garganeeva, N.P.,
Nasyrova, R.F. but are less likely to increase body weight.
Second-generation APs (SGAs) are more likely to cause weight gain
Фармакоэкономическая эффективность применения препарата Луразидон при лечении шизофрении fluctuate in the range of ±30%. Considering the current volume of
antipsychotic drug supply, replacing 100